AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02309801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daidzin
Description: Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
Study NCT02309801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Alcohol single oral dose
Study NCT02309801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol single oral dose
Study NCT00756418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast 5 mg QD 4-weeks.
Study NCT00756418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline 100 to 200 mg BID 4-weeks.
Study NCT03915314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
Study NCT02488005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
Study NCT03377153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin and flaxseed
Description: 2 capsuls hesperidin and 30 g flaxseed
Study NCT03377153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study NCT03892746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS + task oriented practice
Description: Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
Study NCT03892746 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + task oriented practice
Description: Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
Study NCT02686437 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TheraBand Kinesiology Tape
Description: Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
Study NCT04289311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Crisis Alert V2
Description: An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
Study NCT04702841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor modified γδ T cells
Description: Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
Study NCT03607942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMO supplement
Description: HMO supplement will be given three times a day, not mixed with any feeding.
Study NCT03607942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
Study NCT03902314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Iv
Description: Intravenous infusion
Study NCT03902314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Intravenous infusion
Study NCT01668849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape extract
Description: Grape extract self-administered by mouth daily for 35 days
Study NCT01668849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lortab, Fentanyl patch, mouthwash
Description: Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
Study NCT02743013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 100/6/12,5 pMDI
Study NCT02743013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 100/6/12,5 DPI Test 1
Study NCT02743013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 100/6/12,5 DPI Test 2
Study NCT02743013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 100/6/12,5 pMDI replicate
Study NCT02743013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber
Study NCT04184297 — intervention group
Intervention type: DRUG
Intervention: Tiotropium and Olodaterol (Tio+Olo)
Description: drug
Study NCT04184297 — intervention group
Intervention type: DRUG
Intervention: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Description: drug
Study NCT03089580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light Therapy
Description: Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
Study NCT03089580 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment
Description: The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
Study NCT00977626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 - AZD2423 or Placebo
Description: AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
Study NCT00977626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 - AZD2423
Description: AZD2423 Oral solution, multiple dosing
Study NCT00977626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 3 - AZD2423
Description: AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
Study NCT03127293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA
Description: Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
Study NCT02326597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid Tool
Description: The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
Study NCT02326597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
Study NCT02326597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Practice
Description: Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
Study NCT03642652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Text reminders to mobile telephone
Study NCT05937061 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample analysis
Description: Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.
Study NCT05937061 — intervention group
Intervention type: OTHER
Intervention: Anthropometrics measurement - at inclusion to the study (all groups).
Description: Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.
Study NCT05937061 — intervention group
Intervention type: RADIATION
Intervention: Bone mineral density measurement (DXA)
Description: Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
Study NCT02686437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraBand Kinesiology Tape
Description: Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
Study NCT02777866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infiltration of 0.5% Bupivacaine
Description: Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
Study NCT02777866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Infiltration of 0.9% Saline Solution
Description: Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
Study NCT03051152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D1 gastrectomy
Description: Gastrectomy with limited lymph node dissection
Study NCT01147653 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous UCB Reinfusion
Description: Autologous umbilical cord blood (UCB) reinfusion
Study NCT01147653 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous UCB Reinfusion
Description: Autologous umbilical cord blood (UCB) reinfusion
Study NCT01147653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01147653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04143451 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip tetra
Description: quadrivalent influenza vaccine
Study NCT04143451 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone high-dose
Description: high-dose trivalent influenza vaccine
Study NCT04143451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara 5% Topical Cream
Description: imiquimod cream
Study NCT04143451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream BP
Description: inactive aqueous cream
Study NCT03880721 — intervention group
Intervention type: PROCEDURE
Intervention: Microwave abaltion
Description: Use microwave ablation to treat hepatocellular carcinoma
Study NCT00903981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: 2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
Study NCT00903981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: 2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
Study NCT00903981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
Study NCT02765984 — intervention group
Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
Study NCT01345084 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: 66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
Study NCT01345084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
Study NCT01345084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2, IV, doses every 3 weeks (a total of three doses)
Study NCT03302481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liver biopsy
Description: the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
Study NCT01838005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer
Description: Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
Study NCT03493490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neodolpasse
Description: Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Study NCT03493490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Study NCT03493490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Study NCT02944318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Movement Program
Description: The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
Study NCT04818359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoviS Training
Description: Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
Study NCT03051152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Description: Gastrectomy with extended lymph node dissection
Study NCT01161212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical education sessions
Description: 3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
Study NCT01161212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical education sessions
Description: 1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
Study NCT04056234 — intervention group
Intervention type: PROCEDURE
Intervention: Joint puncture
Description: Patient requiring joint puncture for diagnostic or therapeutic reasons.
Study NCT03279120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR
Description: Used for 90 days (Continuous or Interrupted)
Study NCT03279120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used for 90 days (Continuous or Interrupted)
Study NCT00659945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant plus Ondansetron
Description: Aprepitant plus Ondansetron
Study NCT00659945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron plus placebo
Description: Ondansetron plus placebo
Study NCT02866721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation.
Study NCT03532048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Papás Saludables, Niños Saludables Program
Description: Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
Study NCT03532048 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Papás Saludables, Niños Saludables Wait-list Control
Description: The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
Study NCT05417373 — intervention group
Intervention type: OTHER
Intervention: calculated radscore
Description: The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
Study NCT02708576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM313
Study NCT05937061 — intervention group
Intervention type: OTHER
Intervention: Influence of food allergy on growth (intervention groups)
Description: Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
Study NCT02769754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Hemopatch will be apply once the standard surgical hemostasis is achieved.
Study NCT02769754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No additional treatment will be applied after performing the usual surgical hemostasis.
Study NCT01420328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks
Study NCT01420328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment for 6 weeks
Study NCT00842959 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Invent ZO
Description: monofocal aspheric IOL for implantation into capsular bag
Study NCT00842959 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: XL Stabi ZO
Description: monofocal aspheric IOL for implantation into capsular bag
Study NCT02903602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing Histories training method for CHW
Description: Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
Study NCT02903602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard training method for CHW
Description: Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
Study NCT02708576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo